Abstract
We have now applied the enzyme immunoassay using anti-NGF monoclonal antibody (MAb) 27/21 and a blocking test validating the specificity of the immunoreactivity for NGF in serum samples to examine NGF levels in normal rat sera, hemiparkinsonian rat sera, normal monkey sera, and MPTP-treated monkey sera. The levels of NGF in treated animals showed reductions when compared with serum from normal animals. The NGF level alterations observed in lesioned animals and in human parkinsonian patients evidence a relationship between this neurotrophic factor and the neurodegenerative changes observed in Parkinson disease (PD).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bankiewicz K. S., Oldfield E. H., Chiueh C. C., Doppman J. L., Jacobowitz D. M., and Kopin I. J. (1986) Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).Life Sci. 39, 7–16.
Lorigados L., Söderström S., and Ebendal T. (1992) Two-site enzyme immunoassay for βNGF applied to human patient sera.J. Neurosci. Res. 32, 329–339.
Marshall J. F. and Ungerstedt U. (1977) Supersensitivity to apomorphine following destruction of the ascending dopamine neurons: quantification using the rotational model.Eur. J. Pharmacol. 31, 361–367.
Söderström S., Hallbook F., Ibañez C. F., Persson H., and Ebendal T. (1990) Recombinant human β-nerve growth factor (NGF): Biological activity and properties in an enzyme immunoassay.J. Neurosci. Res. 27, 665–677.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lorigados, L., Alvarez, P., Pavón, N. et al. NGF in experimental models of parkinson disease. Molecular and Chemical Neuropathology 28, 225–228 (1996). https://doi.org/10.1007/BF02815226
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02815226